FDA clears Medtronic pacemaker

The FDA approves Medtronic's (MDT +0.1%) newest cardiac resynchronization therapy-pacemaker, Viva CRT-P, for patients with heart failure or atrioventricular block. The pacer incorporates the company's proprietary AdaptivCRT alogrithm which preserves normal heart rhythms while automatically adjusting to the patient's needs, creating a customized therapy for each individual.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs